Trifluoroacetic acid → HCID 118216573, compound
Reaction equation
C(O)(C(F)(F)F)=O.[OH:8][C:9]1([CH2:22][N:23]2[CH:27]=[C:26]([C:28]3[CH:33]=[C:32]([NH:34][C:35]4[N:40]=[C:39]([C:41]([F:44])([F:43])[F:42])[CH:38]=[CH:37][N:36]=4)[CH:31]=[C:30]([CH3:45])[CH:29]=3)[CH:25]=[N:24]2)[CH2:14][CH2:13][N:12](C(OC(C)(C)C)=O)[CH2:11][CH2:10]1>ClCCl>[CH3:45][C:30]1[CH:29]=[C:28]([C:26]2[CH:25]=[N:24][N:23]([CH2:22][C:9]3([OH:8])[CH2:14][CH2:13][NH:12][CH2:11][CH2:10]3)[CH:27]=2)[CH:33]=[C:32]([NH:34][C:35]2[N:40]=[C:39]([C:41]([F:43])([F:44])[F:42])[CH:38]=[CH:37][N:36]=2)[CH:31]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
TFA (0.1 mL 1.298 mmol) was added to the solution of racemic tert-butyl 4-hydroxy-4-((4-(3-methyl-5-((4-(trifluoromethyl) pyrimidin-2-yl)amino)phenyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate (120 mg, 0.23 mmol) in dichloromethane (1 mL). The mixture was stirred at room temperature for 2 days. Additional TFA (0.2 mL) was added and the mixture was stirred for 16 hours. The mixture was purified on reverse phase HPLC (ACN/water with 0.1% TFA modifier) to afford 4-((4-(3-methyl-5-((4-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)-1H-pyrazol-1-yl)methyl)piperidin-4-ol. MS ESI calc'd for C21H24F3N6O [M+H]+433. found 433. 1H NMR (500 MHz, CD3OD) δ 8.65 (d, J=4.8, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.83 (s, 1H), 7.31 (s, 1H), 7.06 (s, 1H), 7.05 (d, J=4.2, 1H), 4.20 (s, 2H), 3.31-3.17 (m, 4H), 2.33 (s, 3H), 1.94-1.78 (m, 2H), 1.73-1.65 (m, 2H).
Workup
- stirringthe mixture was stirred for 16 hours
- customThe mixture was purified on reverse phase HPLC (ACN/water with 0.1% TFA modifier)
Sources & evidence
- ORD record
- ord-6897d5405ab74f639b165cb84458c869
- Source dataset
- uspto-grants-2016_01
- Patent number
- US09242984B2
Reaction notes
Loading…